Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Daniel Wicklein, Nuno Ramos Leal, Johannes Salamon, Mohammed Thamer, Harald Herrmann, Peter Valent, Udo Schumacher, Sebastian Ullrich
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/2cb6ae5dc92e4ce0b5e07086ec54e5a7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!